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When detected early, inexpensive measures can slow chronic kidney disease progression
to kidney failure which, for children, confers significant morbidity and impacts growth and
development. Our objective was to determine the incidence of late presentation of childhood
chronic kidney disease and its associated risk factors.
Methods
We searched MEDLINE, Embase, PubMed, Web of Science, Cochrane Library and CINAHL,
grey literature and registry websites for observational data describing children <21 years pre-
senting to nephrology services, with reference to late presentation (or synonyms thereof).
Independent second review of eligibility, data extraction, and risk of bias was undertaken.
Meta-analysis was used to generate pooled proportions for late presentation by definition
and investigate risk factors. Meta-regression was undertaken to explore heterogeneity.
Results
Forty-five sources containing data from 30 countries were included, comprising 19,339 chil-
dren. Most studies (37, n = 15,772) described children first presenting in kidney failure as a
proportion of the chronic kidney disease population (mean proportion 0.43, 95% CI 0.34–
0.54). Using this definition, the median incidence was 2.1 (IQR 0.9–3.9) per million age-
related population. Risk associations included non-congenital disease and older age. Stud-
ies of hospitalised patients, or from low- or middle-income countries, that had older study
populations than high-income countries, had higher proportions of late presentation.
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Conclusions
Late presentation is a global problem among children with chronic kidney disease, with
higher proportions seen in studies of hospitalised children or from low/middle-income coun-
tries. Children presenting late are older and more likely to have non-congenital kidney dis-
ease than timely presenting children. A consensus definition is important to further our
understanding and local populations should identify modifiable barriers beyond age and dis-
ease to improve access to care.
Introduction
Chronic kidney disease (CKD) in children and young people is a significant health problem
associated with impaired growth, bone disease, cardiovascular morbidity, and a reduced life
expectancy [1–3]. Furthermore, poorer health-related quality of life and psychosocial function-
ing is seen compared to healthy controls, which extends into early adulthood [4–6]. Although
data are limited, population-based studies suggest up to 1% of the child population may have
reduced kidney function [7]. Progression to kidney failure requires life-long kidney replace-
ment therapy (KRT) as dialysis or kidney transplantation for survival, which is costly and unaf-
fordable for many health-care budgets worldwide. A recent global systematic review estimated
that while 2.6 million people received KRT in 2010, this was likely represented only half of all
those requiring life-sustaining treatment [8]. Paediatric-specific estimates suggest that the
median incidence of KRT-treated ESKD is 9 (range 4–18) cases per million of the age-related
population [9].
International efforts are progressively directed towards timely identification of CKD given
the increasing appreciation of its contribution to the global burden of non-communicable dis-
ease. When detected early, inexpensive measures can delay or slow disease progression to kid-
ney failure, thus mitigating costs associated with KRT provision [10]. Implementing these
strategies however is dependent both on timely recognition of CKD and appropriate access to
healthcare. For many children, diagnosis of CKD occurs when kidney function is already
severely reduced [11], although the reasons for this are not fully understood. In adults, risk fac-
tors for late presentation include older age, multi-morbidity, Black or Hispanic ethnicity, and
being uninsured; lack of communication between primary and specialist care can also influ-
ence timing of referral [12]. These results may not be generalizable to children given differ-
ences in kidney disease aetiology and management.
Our aim was to conduct a systematic review of the epidemiological and clinical literature to
determine the incidence and proportion of late presentation of childhood CKD and associated
risk factors.
Materials and methods
We performed a systematic review to identify studies describing the proportion (within the
clinical population) or incidence (with reference to the general population) of children pre-
senting late to specialist or hospital services with CKD. A review protocol was registered with
an international systematic review database (www.crd.york.ac.uk/prospero, reference:
CRD42017064098). Findings are reported in accordance with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses checklist [13].
Studies that described first presentation of incident children with CKD and/or kidney fail-
ure, with reference to late or delayed presentation/referral (or synonyms thereof) were
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included. As there is no consensus definition for late presentation in children, all published
definitions were accepted. Similarly, studies describing paediatric populations aged up to 21
years were included. Comparable studies describing stage of kidney function at presentation
or diagnosis that did not reference late presentation were also included. Reports focusing on
specific disease types or age-groups (e.g. adolescents) were excluded.
With support from an experienced information specialist, a comprehensive search strategy
was developed (S1 Fig) and adapted to search six databases: Ovid MEDLINE, EMBASE,
CINAHL, PubMed, the Cochrane library, and Web of Science (science and social science cita-
tion indices). The first search was performed in September 2017, which was repeated in 2019
(results limited to the previous 2-years). Forward- and backward-reference searches were
undertaken. Five grey literature databases were searched (S2 Fig). Kidney registry websites
with good public accessibility were also examined for relevant reports [14]. We included all
non-English studies, although only English grey literature was explored. Data available in pub-
lished abstracts form only was excluded. Studies published between 1 January 1990 and 10 Sep-
tember 2019 which were available in paper or electronic form were included: this time-frame
was chosen to adequately capture studies from established paediatric nephrology centres and
reflect modern specialist healthcare access globally.
References were imported into EndNoteTM which was used to remove duplicates. L.P
screened titles and abstracts of all studies to identify those meeting the pre-determined eligibil-
ity criteria. E.J.B screened a proportion (20%) of the original search, with 99.9% agreement
between reviewers. Any differences were resolved through discussion. Google Translate was
used to determine eligibility of non-English studies; where necessary, formal full-text transla-
tion was undertaken. We sought to contact authors where clarity was required over the inci-
dent or prevalent nature of the study cohort. For registry data, the most comprehensive data
available, whether from annual report or publication, were used.
A data extraction proforma was devised and piloted prior to use. For studies reporting all
incident kidney disease, numbers of children with CKD were used as the denominator popula-
tion to ensure comparability across studies. A second reviewer (E.J.B) performed independent
data extraction for 20% of studies from the original search. There was 100% agreement
between data extractors.
A modified Newcastle-Ottawa scale (NOS) [15] was devised to quantify risk of bias relevant
to the study aim, which may have contrasted from the study’s original purpose (S1 Table). L.P
performed a risk of bias assessment for all included studies; independent second review (E.J.B)
was undertaken for 20% of studies from the original search, with disagreements resolved
through discussion.
Data analysis
A descriptive analysis was undertaken for included studies according to late presentation defi-
nition used. The terminology contained within this report aligns with recommendations from
Kidney Disease Improving Global Outcomes (KDIGO) consensus conference on nomencla-
ture for kidney function and disease [16], although reference to study-specific terminology is
made. For studies containing population data, the annual incidence of late presentation was
calculated per million of the age-related population (pmarp). Where possible, meta-analysis of
the proportion of LP for individual studies was performed by study definition, using a random
effects (DerSimonian-Laird) model due to expected high heterogeneity among studies. Score
confidence intervals (CI) and Freeman-Tukey double arcsine transformation were used to
ensure admissible confidence intervals for individual and pooled proportions respectively
[17]. Pooled risk ratios (RR) from meta-analysis of clinical and demographic data were
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calculated to explore risk associations with late presentation. Publication bias was evaluated
using a funnel plot, Begg’s test and Egger’s linear regression. All analyses were conducted
using Stata v15.
Results
We identified 49 studies meeting inclusion criteria for our systematic review. Fig 1 outlines the
result of our searches, with reasons for exclusion at each stage. Of the eligible studies, 4 were
removed from further analysis [18–20], leaving 45 studies (S2 Table). Five late presentation
descriptions were identified (Table 1).
Group one (37 studies): Advanced kidney disease/kidney failure at first
presentation (denominator: CKD population [21–57]
Group 1 studies comprised 15,772 participants with a median sample size of 139 (interquartile
range, IQR 48–305, Table 2). Most studies were small, single-centre and from low- or middle-
income countries (LMIC, 75.7%). Functional thresholds for inclusion differed across studies:
most common was an estimated glomerular filtration rate (eGFR) of<60ml/min/1.73m2 used
in 10 studies (27.0%). The upper eGFR inclusion threshold for remaining studies ranged from
25 to>90 ml/min/1.73m2. Four studies used serum creatinine levels to determine eligibility; 1
study did not report a threshold value.
Within this group, variations in the description of late presentation were also noted. The
term ‘kidney failure’ or ‘end-stage kidney disease’ itself carried different meanings: 18 studies
referred to kidney failure as an eGFR of<15ml/min/1.73m2 (48.6%); in 9 studies (24.3%) a
threshold of<10 ml/min/1.73m2 was used. Two studies did not offer a value or reference,
while 1 study defined kidney failure as requiring KRT or death from kidney failure. Five stud-
ies included stage 4 CKD in reference to late presentation while 2 described children with an
eGFR at presentation of<25 ml/min/1.73m2.
Group two (8 studies): First presentation in kidney failure and/or
requirement for KRT within specified time-frame (denominator: Incident
kidney failure population) [11,58–64]
Group 2 studies included 3,567 participants with a median sample size of 146 (IQR 50–779,
Table 3). Compared with group 1, group 2 studies were more likely to come from high-income
countries (HIC, p = 0.01); half were multi-centre in design with data from 5 studies (62.5%)
obtained from a registry dataset. Seven studies included in this group used a requirement for
KRT as a means of identifying the study cohort, with 1 study including children who died
from kidney failure. One study described children presenting to nephrology care, all of whom
developed kidney failure within a 6-month time-frame and was therefore included in this
group. Again, within this group differences in time-based definitions were noted: 3 studies
used a 3-month time-frame between presentation and KRT start to define late presentation
[11,58,59]; 2 studies used 1 month [60,61]; 1 study described a 6-month time-frame [62]. Two
studies described the proportion of children not known to nephrologists before starting KRT
[63,64].
Group three (3 studies): eGFR-based threshold definition (incident kidney
failure population) [11,58,61]
Three studies [11,58,61] from Australia, UK and Europe respectively, offered additional data
describing the proportion of incident children with kidney failure with a low eGFR at
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presentation to nephrology services. All were retrospective analyses of registry data, 2 were
multi-centre in design. Two studies [11,58] used <30ml/min/1.73m2 while 1 study [61] used
�20 ml/min/1.73m2 to define low kidney function at first review.
Group four (2 studies): Time delay between symptom onset and diagnosis
of CKD >3 months [24,44]
Two Nigerian, single-centre studies (252 children, 55.1% male) described the proportion of
incident children who experienced symptoms for>3 months before attendance. The study
cohort was identified from paediatric nephrology referrals in 1 and hospital admissions in
another. Both were retrospective in design and included children aged�16 years. Another
Nigerian single-centre study reported a mean duration of symptoms of 21.2 (standard devia-
tion 5.8) weeks [31]; due to a lack of comparable data, this study was not included.
Group five (2 studies): Time delay between presentation and paediatric
nephrology referral [21,22]
Two single-centre, retrospective studies with a total sample size of 176 patients (67.0% male),
described time delays to nephrology referral. This was evidenced by disparities in mean age at
initial presentation and subsequent paediatric nephrology referral, with differences of 1.7 and
2.1 years reported.
The median modified NOS percentage score for published studies was 75.0% (IQR 75.0–
100.0). Study populations were commonly incident patients attending single-centre paediatric
nephrology services, although 9/45 studies (20.0%) sampled hospital admissions only and
therefore may not be representative of all children presenting to specialist care. Most registry-
based studies relied on voluntary reporting of cases which raises the possibility of under-repre-
sentation. Furthermore, reporting of exclusion criteria was limited and varied widely (S2
Table), restricting assessment of selection bias. Four studies were identified as having an ana-
lytic component relevant to our study aim however only 2 adjusted for potential confounders,
leaving the remainder open to confounding bias. All but 2 studies specified use of data collated
Fig 1. PRISMA diagram. �24 papers were identified from additional sources. Abbreviations: CKD, Chronic Kidney Disease; ESKD, End-stage Kidney Disease (term
used synonymously with ‘kidney failure’).
https://doi.org/10.1371/journal.pone.0244709.g001







1 Advanced kidney disease/ESKD/kidney failure at first presentation
(denominator: CKD population)
37 15772
2 First presentation in ESKD/kidney failure and/or requirement for KRT
within specified timeframe (denominator: incident ESKD/kidney
failure population)
8 3567
3 Estimated glomerular filtration rate-based threshold (denominator:
incident ESKD/kidney failure population)
3 1427
4 Time delay between symptom onset and diagnosis of CKD >3 months 2 252
5 Time delay between secondary and tertiary care referral 2 176
Abbreviations: CKD, Chronic Kidney Disease; ESKD, End-Stage Kidney Disease (used synonymously with ‘kidney
failure’).
https://doi.org/10.1371/journal.pone.0244709.t001
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Table 2. Group one: Study characteristics and findings (Group 1, n = 37) [21–57].
Study characteristics Number (%) Study findings Number (%)
Study location: Number of participants
Asia 19 (51.4) Range 3–6969
Africa 7 (18.9) Mean (SD) 426 (1153)
Europe 6 (16.2) Median (IQR) 139 (48–305)
North America 5 (13.5)
Low-middle income country 28 (75.7)
Year(s) of study: Sex: n (%) n = 29 studies:
Range 1990–2014 Male 4092 (60.9)
Median year of publication (IQR) 2010 (2005–2014) Female 2628 (39.1)
Duration of study (years): Age of participants:
Median (IQR) 6.0 (3.0–10.0) Mean age (SD) n = 18 studies 8�1 (2.7)
Range 1.0–17.0 Median age (IQR) n = 11 studies 9 (5.6–12.5)
Sampling method: Kidney function at first presentation:
Single centre 26 (70.3) Mean eGFR (SD) n = 10 studies 28.2 (18.5)
Multi-centre 11 (29.7) Median eGFR (IQR) n = 5 studies 18.5 (14.9–30.5)
Studies using registry data 6 (16.1)
Age inclusion Late presentation definitions used
<12 years 2 (5.4) Stage 4 or 5 CKD 5 (13.5)
<13 years 1 (2.7) eGFR <25 ml/min/1.73m2 2 (5.4)
<14 years 1 (2.7) Stage 5 (eGFR <15) 18 (48.6)
<15 years 3 (8.1)) Creatinine clearance/eGFR <10 9 (24.3)
<16 years 6 (16.2) ‘End-stage kidney disease’–value not reported 2 (5.4)
<17 years 6 (16.2) Requiring KRT or death 1 (2.7)
<18 years 3 (8.1)
<19 years 10 (27.0)
<20 years 4 (10.8)
<21 years 1 (2.7)
CKD inclusion criteria Modified NOS Score�
Any CKD stage (1–5) 3 (8.1) Median score (max possible score 4 points) n = 36 studies 3 (3.0–4.0)
eGFR <90ml/min/1.73m2 5 (13.5) Median percentage score (IQR) 75 (75.0–100.0)
eGFR <75 ml/min/1.73m2 4 (10.8)
eGFR <60 ml/min/1.73m2 10 (27.0)
eGFR <50 ml/min/1.73m2 7 (18.9)
eGFR <25 ml/min/1.73m2 1 (2.7)
Clinical assessment only 2 (5.4)
Creatinine based criteria 4 (10.8)
Not reported 1 (2.7)
CKD duration threshold
No duration reported 16 (43.2)
3 months/less if clinical evidence 4 (10.8)
�3 months 15 (40.5)
6 months 1 (2.7)
12 months 1 (2.7)
Guidelines for CKD staging used:
NKF-K/DOQI 16 (43.2)
KDIGO 4 (10.8)
Textbook definition used 1 (2.7)
(Continued)
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Table 2. (Continued)
Study characteristics Number (%) Study findings Number (%)
Not reported 15 (40.5)
Country-specific guidelines 1 (2.7)
Abbreviations: CKD, Chronic Kidney Disease; eGFR, estimated Glomerular Filtration Rate; IQR, Interquartile Range; KDIGO, Kidney Disease Improving Global
Outcomes; KRT, Kidney Replacement Therapy; NKF-K/DOQI, National Kidney Federation- Kidney Disease Outcomes Quality Initiative; SD, Standard Deviation.
�Does not include annual report from the North American Pediatric Renal Trials and Collaborative Studies group.
https://doi.org/10.1371/journal.pone.0244709.t002
Table 3. Summary of study population characteristics for studies reporting first presentation in end-stage kidney disease and/or requirement for KRT within speci-
fied timeframe (denominator: Incident ESKD/kidney failure population) (Group 2, n = 8) [11,58–64].
Study characteristics Number (%) Study findings Number (%)
Study location: Number of participants 3567
Africa 2 (25.0) Range 15–1603
Australasia 1 (12.5) Mean (SD) 446 (615)
North America 1 (12.5) Median (IQR) 146 (50–779)
Europe 4 (50.0)
Low-middle income countryꝉ 2 (28.6)
Year(s) of study: Sex: n = 5 studies
Range 1978–2012 Male 1295 (56.9)
Median year of publication (IQR) 2010 (2007–
2013)
Female 979 (43.1)
Duration of study (years): Age of participants:
Median (IQR) 7.0 (3.5–14.6) Mean age (SD) n = 3 studies 10.9 (3.0)
Range 1.0–28.0 Median age (IQR) n = 2 studies 7.8 (4.1–11.5)
Sampling method: Kidney function at first presentation:
Single centre 4 (50.0) Median eGFR n = 1 study 14.8
Multi-centre 4 (50.0)
Studies using registry data 5 (62.5)
Age inclusion Late presentation definitions used
<16 years 2 (25.0) Not known to nephrology services before reaching kidney failure/ESKD 2 (25.0)
<18 years 4 (50.0) Referral within 1 month of KRT start
<19 years 1 (12.5) Referral <3 months (90 days) before KRT start 2 (25.0)
<21 years 1 (12.5) Development of kidney failure/ESKD within 6 months of first presentation 3 (37.5)
Eligibility threshold
Need for KRT or death from kidney
failure
7 (87.5)
Not recorded 1 (12.5) 1 (12.5)
CKD duration threshold Modified NOS Score�
No duration reported 7 (87.5) Median score for descriptive studies (max possible score 4 points) n = 3 studies
(IQR)
3.0 (2.0–3.5)
� 3 months/less if clinical evidence 1 (12.5) Median score for analytic studies (max possible score 6 points) n = 4 studies (IQR) 5 (3.8–6.0)
All studies: median percentage score (IQR) 75.0 (58.3–
100.0)
Abbreviations: CKD, chronic kidney disease; ESKD, End-Stage Kidney Disease (used synonymously with ‘kidney failure’); IQR, interquartile range; KRT, Kidney
Replacement Therapy; SD, Standard Deviation.
�Does not include annual report from the US Renal Data System.
ꝉDoes not include multi-centre European paper in analysis.
https://doi.org/10.1371/journal.pone.0244709.t003
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from medical or registry records to identify cases, minimising the risk of information bias.
Two studies offered no diagnostic criteria which may cause misclassification bias.
Table 4 provides the pooled and individual effect estimates (proportions) of late presenta-
tion for studies by definition-group. Group 5 studies which used summary age measures to
highlight referral delays were excluded. Overall, a high levels of heterogeneity were noted (I2
>95%). Population figures to calculate incidence were available for 15 group 1 studies covering
14 regions: 2 studies [35,37] described coverage of 1 geographical area (Vietnam) and were
combined. The median annual incidence of late presentation was 2.1 (IQR 0.9–3.9) pmarp. A
sensitivity analysis excluding studies at high risk of bias (NOS percentage score below median)
did not significantly alter pooled proportions overall or by definition-group. Additionally,
restricting data to the most recent study from each centre or region did not significantly alter
findings.
Sex [11,23,58,59,63] and disease [11,23,25,51,63] data were available from 5 studies, while 4
contained mean age data [23,58,59,60] (Figs 2–4). No association was seen between sex and
late presentation (RR 0.89, 95% CI 0.65, 1.21, p = 0.46). Congenital anomalies of the kidneys
and urinary tract were associated with a reduced risk of LP (RR 0.60, 95% CI 0.44, 0.82,
p = 0.001), although due to heterogeneity in disease groupings, this could not be analysed in
further detail. There was strong evidence for a difference in age at presentation (standardised
mean difference 0.47 years, 95% CI 0.22, 0.72 p<0.001), with a higher mean age noted among
late presenting children.
Two studies provided unadjusted data for other risk factors including low socio-economic
status (SES) and geographical remoteness respectively. Michael and Gabreil [31] described a
cohort of children all presenting with an eGFR of<25ml/min/1.73m2 of which 87.5% were of
low SES, although the definition and measure of SES used was unavailable. Kennedy et al.
reported 36% of late presenting children lived in remote regions compared to 6% of those with
timely presentation (p = 0.03) [58]. Qualitative text analysis was undertaken to identify features
described but not substantiated that may be linked to late presentation; these included low
socioeconomic status and costs associated with healthcare [21,33,36,44] living in remote areas
[33], delayed referral to tertiary care [45], ‘traditional habits’ of first seeking healthcare from
traditional healers and a lack of specialist education in local hospitals [37].
Begg’s test suggested no evidence (p = 0.53) however Egger’s test showed strong evidence of
publication bias (coefficient -1.17, p<0.001). This was supported by funnel plot asymmetry (S3
Fig) with an over-representation of studies with higher proportions of late presentation.
A meta-regression was performed to determine if the high heterogeneity could be explained
by study or ecological covariates. Analysis was restricted to groups 1 and 2. For each study,
odds of late presentation were converted to a log-odds scale and a standard error of the log
odds calculated. Where studies contained zero-event cells, a continuity correction of 0.5 was
added to the number of events and non-events and 1 added to the total study size, to enable
inclusion. Covariates of importance were determined a priori and included study-level (e.g.
group definition, study design (single- or multi-centre), setting (all nephrology referrals versus
hospital admissions only)) and ecological variables including summary measures of age and
presenting eGFR. Income (LMIC versus HIC) of the study country, as defined by the World
Bank [65] was also examined. For continuous variables, median values were preferred; how-
ever, to improve power and given similarities in regression coefficients, mean values were
included where data were missing.
Table 5 highlights meta-regression findings. Country income, study setting, and age of
study cohort were predictive of heterogeneity on univariable analysis. A strong correlation,
however, was noted between age and country income, with a lower age at presentation among
HIC studies. It was hypothesised that age may mediate the association between country
PLOS ONE Incidence of and risk factors for late presentation of childhood chronic kidney disease
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Table 4. Late presentation proportion and incidence rates by study definition.












Advanced kidney disease/ESKD at first presentation (denominator: CKD population)
Mattoo, 1990 Saudi Arabia <14 years Creatinine
>180μmol/L (2mg/
dL)
Requiring KRT or death 0.35 (0.26, 0.45) 2.78
Al Harbi, 1997 Saudi Arabia <13 years Creatinine
>177 μmol/L (2mg/
dL)
CrCl <10 0.37 (0.26, 0.50) 2.73 9.2
Gulati, 1999 India <17 years Creatinine
>180μmol/L (2mg/
dL)
ESKD (value not given) 0.54 (0.40, 0.67) 2.70 0.4
Hafeez, 2002 India <16 years eGFR <75 eGFR <10 0.60 (0.44, 0.73) 2.68
Ardissino, 2003 Italy <20 years eGFR <75 CrCl <25 0.26 (0.24, 0.29) 2.85
Olowu, 2003 Nigeria <16 years eGFR <60 eGFR <10 0.33 (0.17, 0.55) 2.52 1.1
Hari, 2003 India <19 years eGFR <50 eGFR <10 0.30 (0.25, 0.35) 2.83
Michael, 2004 Nigeria <17 years eGFR <25 eGFR <25 1.00 (0.86, 1.00) 2.56
Yang, 2004 China <15 years eGFR <50 Stages 4/5 CKD 0.81 (0.78, 0.83) 2.85
Saeed, 2005 Syria <16 years eGFR <50 eGFR <10 0.61 (0.39, 0.80) 2.48
Kari, 2006 Saudi Arabia <15 years eGFR <50 eGFR <10 0.52 (0.40, 0.63) 2.74
Hassan, 2007 Iraq <18 years eGFR <50 eGFR <10 0.36 (0.28, 0.46) 2.78
Mong Hiep,
2008
Vietnam <19 years Not reported eGFR <15 0.85 (0.81, 0.89) 2.83 2.3^
NAPRTCS,
2008
United States <21 years eGFR <75 eGFR <15 0.12 (0.11, 0.13) 2.85 0.7
Miller, 2009 Jamaica <12 years eGFR <50 ESKD (value not given) 0.28 (0.12, 0.51) 2.48 1.4
Bek, 2009 Turkey <19 years eGFR <75 eGFR <15 0.33 (0.27, 0.38) 2.83 3.6
Huong, 2009 Vietnam <18 years Creatinine
>150μmol/L (1.7
mg/dL)
eGFR <15 0.65 (0.57, 0.72) 2.80
Ahmadzadeh,
2009
Iran <17 years eGFR <60 eGFR <10 0.22 (0.16, 0.30) 2.80
Mong Hiep,
2010
Belgium <20 years eGFR <60 eGFR <15 0.14 (0.09, 0.21) 2.80 1.7
Peco-Antic,
2011
Serbia <19 years eGFR <90 eGFR <15 0.29 (0.24, 0.34) 2.83 5.8
Gheissari, 2012 Iran <19 years eGFR <60 eGFR <15 0.74 (0.69, 0.79) 2.82
Paripović, 2012 Serbia <19 years eGFR <90 Stages 4/5 0.31 (0.23, 0.41) 2.77
Olowu, 2013 Nigeria <17 years All CKD stages (1–5) eGFR <15 0.19 (0.13, 0.26) 2.80
Kim, 2013 United
Kingdom
<16 years eGFR <60 eGFR <15 0.14 (0.09, 0.21) 2.80 2.3
Alsaggaf, 2013 Saudi Arabia <17 years eGFR <90 eGFR <15 0.34 (0.29, 0.40) 2.83
Keita, 2014 Senegal <16 years eGFR <60 eGFR <15 0.72 (0.58, 0.82) 2.71
Odetunde, 2014 Nigeria <17 years eGFR <60 Stages 4/5 0.45 (0.35, 0.55) 2.77 0.8
Cerón, 2014 Guatemala <20 years eGFR <90 eGFR <15 or KRT 0.36 (0.32, 0.41) 2.84 2.3
Safouh, 2015 Egypt <20 years All CKD stages (1–5) eGFR <15 0.58 (0.55, 0.61) 2.85 6.5
Kari, 2015 Saudi Arabia <15 years All CKD stages (1–5) eGFR <15 0.16 (0.13, 0.18) 2.85
Montini, 2016 Nicaragua <19 years All CKD stages (1–5) Stages 4/5 0.55 (0.49, 0.61) 2.82 4.2
Miller, 2016 Jamaica <12 years eGFR <60 eGFR <15 0.00 (0.00, 0.12) 2.59 0.0
Qader, 2016 Bangladesh <19 years eGFR <90 eGFR <15 0.57 (0.45, 0.68) 2.74
Yadav, 2016 Nepal <16 years Not reported Stages 4/5 1.00 (0.44, 1.00) 1.58
Halle, 2017 Cameroon <18 years eGFR <60 eGFR <15 0.81 (0.57, 0.93) 2.44
(Continued)
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income and late presentation and was therefore not included in the final model. A lower aggre-
gate eGFR at presentation strongly correlated with higher odds of late presentation on univari-
able analysis, however, due to limited studies with available data we were underpowered to
incorporate in the final model. In the final model, country income and study setting were
strongly associated with greater odds of late presentation. Exclusion of zero-event studies did
not significantly alter effect estimates. Similarly, restricting analysis to most recent published
data by centre or region did not change associations seen.
Table 4. (Continued)












Alparslan, 2017 Turkey <19 years eGFR <60 eGFR <15 0.36 (0.31, 0.43) 2.82
Sandanala, 2018 India <19 years eGFR <50 eGFR <10 0.40 (0.17, 0.69) 2.25
Random pooled effect size 0.43 (0.34, 0.54) 100.0 Median incidence 2.1
(0.9, 3.9)
Requirement for KRT within specified timeframe (denominator: incident ESKD/kidney failure population)
Eke, 1994 Nigeria <16 years Not recorded ESKD within 6 months of
first visit
1.00 (0.80, 1.00) 6.43
Jander, 2006 Poland <19 years Requiring KRT KRT within 1 month of
first visit
0.21 (0.15, 0.27) 13.84
USRDS report,
2008
United States <21 years Requiring KRT Not known to
nephrologist
0.35 (0.33, 0.38) 15.25
van Stralen,
2010
Europe-wide <18 years Requiring KRT KRT within 1 month of
first visit
0.31 (0.26, 0.36) 14.55
Boehm, 2010 Austria <18 years Requiring KRT KRT within 3 months of
first visit
0.24 (0.17, 0.33) 12.97
Kennedy, 2012 Australia <18 years Requiring KRT KRT within 3 months of
first visit
0.30 (0.19, 0.44) 10.62




0.64 (0.51, 0.76) 11.01
Pruthi, 2016 United
Kingdom
<16 years Requiring KRT KRT within 3 months of
first visit
0.25 (0.23, 0.28) 15.32
Random pooled effect size 0.37 (0.29, 0.45) 100.0
eGFR-based threshold (denominator: incident ESKD/kidney failure population)
van Stralen,
2010
Europe <18 years Requiring KRT eGFR�20ml/min/1.73m2 0.59 (0.54, 0.64) 37.60
Kennedy, 2012 Australia Requiring KRT eGFR <30ml/min/1.73m2 0.55 (0.40, 0.69) 22.02
Pruthi, 2016 United
Kingdom
<16 years Requiring KRT eGFR <30ml/min/1.73m2 0.71 (0.68, 0.73) 40.38
Random pooled effect size 0.63 (0.53, 0.73) 100.0
Time delay between symptom onset and diagnosis of CKD >3 months
Olowu, 2013 Nigeria <17 years All stages Symptoms >3 months
before first presentation
0.46 (0.38, 0.54) 61.07
Odentunde,
2014
Nigeria <17 years eGFR <60 Symptoms >3 months
before first presentation
0.62 (0.52, 0.71) 38.93
Random pooled effect size 0.52 (0.46, 0.59) 100.0
Abbreviations: CI, Confidence Interval; CKD, Chronic Kidney Disease; CrCl Creatinine clearance; eGFR, estimated glomerular filtration rate (ml/min/1.73m2); ESKD,
end-stage kidney disease (used synonymously with ‘kidney failure’); KRT, renal replacement therapy; NAPRTCS, North American Pediatric Renal Trials and
Collaborative Studies; USRDS, United States Renal Data System.
�Weight from random effects model
^Studies by Mong Hiep et al. (2008) and Huong et al. (2009) in combination report coverage of paediatric population for Vietnam; country-wide population data for
year of study was therefore used to calculate incidence.
https://doi.org/10.1371/journal.pone.0244709.t004
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Discussion
This systematic review extensively searched published and grey literature for epidemiological
studies reporting the incidence and proportion of late presentation in children, irrespective of
the main aim of the study. It demonstrated the term is commonly used to describe children
with advanced disease, typically kidney failure, at initial presentation to nephrology services.
Using this definition, the pooled proportion of children presenting late was 0.43 (95% CI 0.34–
0.54); the median incidence was 2.1 (IQR 0.9–3.9) pmarp. Other definitions identified
included early requirement for KRT and eGFR-based thresholds among the incident kidney
failure cohort as well as time delays from symptom onset to presentation, and from secondary
to specialist care. Meta-analysis highlighted that older age and non-congenital kidney disease
were associated with greater risk of late presentation, however findings varied across studies.
Considerable heterogeneity was noted between studies, which was partly explained by country
income and study setting. Age of the study cohort was strongly associated with country
income, suggesting national wealth may influence timing of access to nephrology care.
While other global systematic reviews have focused on access to KRT and outcomes for
children with kidney failure [8,66], this is the first study to systematically quantify the burden
of late presentation. Understanding this problem in detail is necessary for several reasons.
First, we have identified late presentation to be a common global phenomenon for children
Fig 2. Risk of late presentation by sex. Abbreviations: CI, confidence interval; RR, Risk Ratio.
https://doi.org/10.1371/journal.pone.0244709.g002
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diagnosed with CKD, with higher proportions noted among LMIC studies. This observation
correlates with recent global estimates [67], suggesting that the burden of kidney disease is car-
ried predominantly by resource-poor countries with limited access to KRT. This reinforces the
urgent need for investment and intervention to support timely diagnosis and delay disease
progression among these populations.
Second, identifying risk factors will enable the development of strategies to detect CKD ear-
lier, as has been demonstrated by community-based adult programmes [68]. Although data
were sparse, we identified greater risk of late presentation for children with non-congenital
disease. Faster progression of CKD is seen among children with glomerular disorders com-
pared with congenital disease which may explain presentation in advanced disease [9]. This
may not be solely due to disease-type but mediated via proteinuria and hypertension [69].
Despite the male predominance often seen among congenital disorders, we did not identify an
association between sex and late presentation. Any differences in CKD progression by sex may
be mediated by disease-type rather than a direct effect of sex [70]. Older age was noted among
late presenting children; both increasing age and the pubertal period have been linked to more
rapid decline of kidney function which may in part explain this finding [29,71].
Fig 3. Risk of late presentation by kidney disease type. CAKUT denotes congenital anomalies of the kidneys and urinary tract. Studies either referenced ‘CAKUT’
disorders or sub-groups including obstructive uropathy, reflux nephropathy and/or renal hypo/dysplasia. Sub-groupings were combined for CAKUT total. Pruthi et al.
reported missing disease data for 11 patients. Abbreviations: CI, confidence interval; RR, Risk Ratio.
https://doi.org/10.1371/journal.pone.0244709.g003
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The risk factors identified in this review are, overall, non-modifiable. What is not clear is
whether there are modifiable factors that may serve as targets for intervention. Many authors
alluded to factors that may hinder access to specialist healthcare, which included geographical
remoteness from centre, socio-economic deprivation, and healthcare costs, however with the
patient-level data available we were unable to substantiate these hypotheses. One Australian
study identified an association between geographical remoteness and late presentation [58]
however due to a lack of adjustment for potential confounders, our ability to interpret these
results are limited.
Understanding the process of how late presenting children are recognised and reach spe-
cialist care, will help to identify opportunities for earlier detection. It will also clarify whether
late referral to specialist care is implicated, as suggested by 2 studies included in this review
[21,22]. Defining symptoms experienced pre-detection will also support strategies for inter-
vention. Although many studies described symptoms at presentation, we were unable to
extract these data by late presentation status. With as many as 50% of children reporting symp-
toms for several months prior to presentation [24,44], use of symptom type in combination
with risk factors such as age could enable targeted use of CKD screening tests within healthcare
settings.
Fig 4. Standardised mean differences in age at presentation between late versus timely presenters. Abbreviations: SMD, standardised mean difference; CI, confidence
interval.
https://doi.org/10.1371/journal.pone.0244709.g004
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Third, appraising the literature provides an opportunity to highlight variations in study
methods and to standardise approaches for future research. Since the publication of the
National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative guideline in 2002
[72] and its adoption by KDIGO in 2005 [73], there has been an internationally-recognised
classification system for children >2 years which uses a threshold of<60ml/min/1.73m2 to
define CKD. Many group 1 studies referenced these guidelines in either defining or staging
CKD (54.1%), however only 10 studies(27.0%) used an eGFR threshold of<60ml/min/1.73m2
for study inclusion, with others using narrower or broader CKD definitions. Variation in func-
tional thresholds to define CKD contributed to the heterogeneity seen, as evidenced by meta-
regression findings. Standardising functional thresholds using international guidance as well
as achieving consensus on what constitutes a ‘paediatric’ population will enable future epide-
miological research to be directly comparable across nations.
This study has several strengths. We extensively searched the literature for studies describ-
ing or referencing late presentation of kidney disease, regardless of the study aim. We
employed a comprehensive search strategy that included forward- and backward-citation
searching and sought to be inclusive of all studies, including those with small sample sizes or
different definitions of late presentation. There are however limitations. To ensure incident
populations were captured, studies describing prevalent populations were excluded; it is possi-
ble that these studies may have contained information relevant to our analysis. Second, a sys-
tematic review is only as good as the quality and content of the included studies. Those
included in this review were generally small, single-centre, descriptive studies derived from
heterogenous clinical populations and are therefore at risk of bias. Given the specialist-based
populations used to determine study cohorts, estimates generated are likely to represent the
‘tip of the iceberg’, with severe CKD being over-represented. Furthermore, our analyses sought
to combine studies with differing inclusion criteria and age thresholds, although efforts to for-
mally quantify heterogeneity using meta-regression were employed to counteract this prob-
lem. It must also be recognised that country income and age of the study cohort represent
aggregate data and may not reflect true associations on an individual level.
Table 5. Univariable and multivariable random effects meta-regression of late presentation of CKD (adjusted R2 of multivariable model 52.6%).
Univariable analysis Multivariable analysis (n = 44 studies)










Group two definition (c.f. group one) 0.77 0.32, 1.87 0.56 - - -
Study from high-income country (c.f. low- or middle-income
income country)
0.33 0.18, 0.60 0.001 0.41 0.24, 0.71 0.002
Multi-centre design (c.f. single-centre) 0.68 0.34, 1.38 0.28 - - -
Hospital admissions (c.f. all paediatric nephrology services) 3.93 1.91, 8.05 <0.001 3.01 1.56, 5.80 0.002
GFR-based inclusion threshold (c.f. creatinine-based threshold) 0.57 0.14, 2.40 0.43 - - -
Study conducted from 2001 onwards (c.f. pre-2001,median
start year)
1.35 0.68, 2.68 0.38 - - -
Large sample size (�140 participants) (c.f. <140 participants,
median sample size)
0.64 0.33, 1.24 0.18 - - -
Study summary ageMedian/mean age of study cohort (per year
increase)
1.23 1.11, 1.36 <0.001 - - -
GFR at presentationMedian/mean estimated glomerular
filtration rate of study cohort (per ml/min/1�73m2 increase)
0.96 0.94, 0.99 0.01 - - -
Abbreviations: CKD, Chronic Kidney Disease; GFR, glomerular filtration rate. �Due to limited number of studies (n = 15), we were underpowered to include GFR at
presentation in the final multivariable model.
https://doi.org/10.1371/journal.pone.0244709.t005
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In conclusion, late presentation, most commonly defined as first presentation to paediatric
nephrology care with kidney failure, is a global phenomenon affecting a large proportion of
children attending specialist services and is more common in older children and those with
non-congenital kidney disease. Studies from LMIC report higher proportions of late presenta-
tion than HIC studies, highlighting an urgent need for interventions to reduce the burden of
late detection in settings with limited access to KRT. International consensus on a definition
for late presentation, as well as age ranges to be included within paediatric studies, will stan-
dardise reporting of epidemiological studies and facilitate comparison of risk associations
across populations. Research is required to explore non-congenital disease associations and
consider other factors implicated in late presentation, such as socio-economic deprivation.
Due to the heterogeneity in estimates observed, a tailored approach is required to determine
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